Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HAO1 | Q9UJM8 | 11/20 | 0.52 |
| ▸ | P2RY14 | Q15391 | 5/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23319935 | 0.90 | HAO1 (0.48) | HAO1KMT2A | |
| SCHEMBL25465031 | 0.86 | HAO1 (0.45) | HAO1P2RY14KMT2AMAPTGRM5 | |
| SCHEMBL29692495 | 0.86 | HAO1 (0.69) | HAO1 | |
| SCHEMBL23001884 | 0.86 | HAO1 (0.69) | HAO1 | |
| SCHEMBL23319889 | 0.84 | HAO1 (0.54) | HAO1KMT2AMAPT | |
| SCHEMBL23319929 | 0.83 | NAPRT (0.41) | HAO1 | |
| SCHEMBL21312442 | 0.82 | GAA (0.45) | HAO1KMT2A | |
| SCHEMBL23001974 | 0.81 | HAO1 (0.47) | HAO1 | |
| SCHEMBL29964033 | 0.81 | HAO1 (0.47) | HAO1 | |
| SCHEMBL23319961 | 0.80 | HAO1 (0.39) | HAO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230143491-A1 | TRIAZOLE GLYCOLATE OXIDASE INHIBITORS | PHOENIX TISSUE REPAIR, INC. | 2023-05-11 | — | — | US | disclosed |
| US-20230143491-A1 | TRIAZOLE GLYCOLATE OXIDASE INHIBITORS | PHOENIX TISSUE REPAIR, INC. | 2023-05-11 | — | — | US | disclosed |
| US-20230143491-A1 | TRIAZOLE GLYCOLATE OXIDASE INHIBITORS | PHOENIX TISSUE REPAIR, INC. | 2023-05-11 | — | — | US | disclosed |
| US-20210403439-A1 | TRIAZOLE GLYCOLATE OXIDASE INHIBITORS | VENTHERA, INC. | 2021-12-30 | — | — | US | disclosed |
| EP-3817816-A1 | TRIAZOLE GLYCOLATE OXIDASE INHIBITORS | Orfan Biotech Inc. (US) | 2021-05-12 | — | — | EP | disclosed |
| CN-112399873-A | Triazole glycolate oxidase inhibitor | 奥凡生物科技公司 | 2021-02-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230143491-A1 | TRIAZOLE GLYCOLATE OXIDASE INHIBITORS | XDH, DUOX1, PNPO | HAO1 6/4885P2RY14 2079/4885KMT2A 3280/4885 |
| US-20210403439-A1 | TRIAZOLE GLYCOLATE OXIDASE INHIBITORS | XDH, DUOX1, PNPO | HAO1 6/4885P2RY14 2079/4885KMT2A 3280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.